Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma, Inc. (Nasdaq: LUMO) is a clinical-stage biotechnology company dedicated to developing innovative therapeutics for rare diseases. Headquartered in the United States, Lumos Pharma focuses on creating treatments for conditions such as cancer and rare growth disorders. The company is active in both clinical-stage and preclinical research, emphasizing molecules that enhance the immune system's ability to fight cancer cells.
The company's portfolio includes orally administered treatments, designed to be used alongside other cancer therapies, and a promising Ebola vaccine. Recent achievements highlight the company's progress in its clinical trials, particularly the Phase 2 trials evaluating LUM-201 for moderate Pediatric Growth Hormone Deficiency (PGHD), which have shown significant results in increasing annualized height velocity (AHV). These advancements underscore Lumos Pharma's commitment to addressing unmet medical needs.
Lumos Pharma engages in strategic partnerships with pharmaceutical companies and contracts with manufacturing organizations to ensure the effective production of its treatments. A notable recent development is the appointment of Dr. Pitukcheewanont as Chief Medical Officer. Dr. Duke, with extensive experience in clinical development and medical affairs, has been integral in the advancement of Lumos Pharma's clinical programs.
Financially, Lumos Pharma is in a stable position, with cash on hand expected to support operations through Q3 2024. The company is also gearing up for a Phase 3 trial for LUM-201, poised to be a double-blinded, placebo-controlled clinical trial with a 2:1 randomization in approximately 150 patients. This trial aims to secure the approval of LUM-201 as the first oral therapeutic for moderate PGHD.
Lumos Pharma continues to exhibit its potential through its robust research initiatives, strategic partnerships, and a dedicated team of experts. The company's proactive approach in clinical and preclinical development projects positions it as a significant player in the biotechnology sector, particularly in the realm of rare diseases.
Lumos Pharma, a biopharmaceutical company, announced the presentation of interim data from its OraGrowtH210 and OraGrowtH212 trials at the Pediatric Endocrine Society's annual meeting in May 2023. The oral presentation, led by Dr. Andrew Dauber, focuses on growth response in subjects treated with LUM-201 for idiopathic Pediatric Growth Hormone Deficiency (iPGHD). Additionally, data from the OraGrowtH212 trial will be showcased in a poster presentation by Dr. Fernando Cassorla. LUM-201 represents a potential alternative to painful growth hormone injections, having received Orphan Drug Designation in the US and EU. This progress highlights Lumos Pharma's commitment to developing effective treatments for rare diseases.
Lumos Pharma, Inc. (NASDAQ:LUMO), based in Austin, Texas, announced that it will report its first quarter 2023 financial results after market close on May 3, 2023. The company is advancing its oral therapeutic candidate, LUM-201, for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials. Following the financial results announcement, Lumos will host a conference call and webcast at 4:30 PM ET, inviting investors and the public to participate in the discussion and Q&A session. LUM-201 aims to provide an alternative to traditional growth hormone injections. It has received Orphan Drug Designation in both the U.S. and EU, highlighting its potential impact in treating rare diseases.
AUSTIN, Texas, March 09, 2023 – Lumos Pharma (NASDAQ:LUMO) announced its participation in Oppenheimer’s 33rd Annual Healthcare Conference, taking place virtually from March 13-15, 2023. Lumos Pharma will present on March 14 from 2:00-2:30 PM EDT and will host one-on-one meetings with investors on the same day. The presentation will focus on the company's oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) currently undergoing Phase 2 trials. Lumos Pharma’s lead candidate, LUM-201, has received Orphan Drug Designation in both the US and EU, offering a potential alternative to traditional growth hormone injections.
Lumos Pharma (NASDAQ:LUMO) presented additional data from its OraGrowtH212 trial at the 2023 International Meeting of Pediatric Endocrinology. The oral presentation highlighted a dose-dependent increase in growth hormone pulsatility and a correlation with heightened growth velocity, with data suggesting a durable response over 12 months. The OraGrowtH210 trial interim analysis indicated an annualized height velocity of 8.6 cm/year at 1.6 mg/kg/day. Both trials are now fully enrolled, with top-line results expected in Q4 2023, reinforcing optimism for LUM-201 as an oral treatment for Pediatric Growth Hormone Deficiency.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
What does Lumos Pharma, Inc. specialize in?
What are some of the key products in Lumos Pharma's pipeline?
Where is Lumos Pharma headquartered?
What is the status of Lumos Pharma's clinical trials?
Who is the Chief Medical Officer of Lumos Pharma?
What partnerships does Lumos Pharma engage in?
What is the financial outlook for Lumos Pharma?
What is LUM-201?
Does Lumos Pharma conduct preclinical research?
How does Lumos Pharma's research contribute to cancer treatment?
